香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Asymchem Laboratories (Tianjin) Co., Ltd. 凱萊英醫藥集團（天津）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 於本公告日期，本公司董事會由董事長兼執行董事Hao Hong博士，執行董事楊蕊 女士、張達先生及洪亮先生，非執行董事Ye Song博士及張婷女士，以及獨立非 執行董事孫雪嬌博士、侯欣一博士及謝維愷先生組成。 董事會會議日期 凱萊英醫藥集團（天津）股份有限公司（「本公司」）董事會（「董事會」）謹此公佈， 董事會會議將於2025年10月30日（星期四）舉行，藉以（其中包括）考慮及批准本 公司及其附屬公司截至2025年9月30日止九個月的第三季度業績及其發佈，以及 處理其他事項（如有）。 承董事會命 凱萊英醫藥集團（天津）股份有限公司 Hao Hong博士 董事長、執行董事兼首席執行官 中國天津，2025年10月15日 （股份代號：6821） ...

Core Viewpoint - The company, Kelaiying (06821.HK), has announced that its board meeting will take place on October 30, 2025, to consider and approve the third-quarter performance for the nine months ending September 30, 2025, along with addressing other matters if necessary [1] Group 1 - The board meeting is scheduled for October 30, 2025 [1] - The meeting will focus on the approval of the company's third-quarter results for the nine months ending September 30, 2025 [1] - Other matters may also be addressed during the meeting [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 凱萊英醫藥集團（天津）股份有限公司（「本公司」）董事會（「董事會」）謹此公佈， 董事會會議將於2025年10月30日（星期四）舉行，藉以（其中包括）考慮及批准本 公司及其附屬公司截至2025年9月30日止九個月的第三季度業績及其發佈，以及 處理其他事項（如有）。 承董事會命 凱萊英醫藥集團（天津）股份有限公司 Hao Hong博士 董事長、執行董事兼首席執行官 中國天津，2025年10月15日 於本公告日期，本公司董事會由董事長兼執行董事Hao Hong博士，執行董事楊蕊 女士、張達先生及洪亮先生，非執行董事Ye Song博士及張婷女士，以及獨立非 執行董事孫雪嬌博士、侯欣一博士及謝維愷先生組成。 Asymchem Laboratories (Tianjin) Co., Ltd. 凱萊英醫藥集團（天津）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6821） 董事會會議日期 ...

Group 1 - The stock price of Kailaiying has dropped 3.24% to 102.00 CNY per share, with a total market capitalization of 36.781 billion CNY, marking a cumulative decline of 10.29% over the last four days [1] - Kailaiying Pharmaceutical Group, established on October 7, 1998, specializes in providing CMO pharmaceutical outsourcing services, with revenue composition of 76.19% from small molecule CDMO solutions and 23.71% from emerging services [1] Group 2 - Huisheng Fund holds a significant position in Kailaiying, with its Huisheng Medical Health 6-Month Holding Period Mixed Fund reducing its holdings by 88,700 shares, now holding 345,300 shares, which constitutes 5.08% of the fund's net value [2] - The fund has experienced a floating loss of approximately 1.1809 million CNY today and a total floating loss of 4.0398 million CNY during the four-day decline [2] - The Huisheng Medical Health 6-Month Holding Period Mixed Fund was established on December 22, 2020, with a current size of 600 million CNY, achieving a year-to-date return of 23.82% and a one-year return of 19.48% [2]

Market Overview - The medical services sector experienced a decline of 2.91% on October 13, with Haoyuan Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3889.5, down 0.19%, while the Shenzhen Component Index closed at 13231.47, down 0.93% [1] Stock Performance - Notable gainers in the medical services sector included: - Meinian Health: closed at 5.29, up 3.52% with a trading volume of 2.2848 million shares [1] - ST Biological: closed at 9.15, up 2.69% with a trading volume of 23,400 shares [1] - International Medical: closed at 4.98, up 2.26% with a trading volume of 356,400 shares [1] - Major decliners included: - Haoyuan Pharmaceutical: closed at 75.50, down 6.79% with a trading volume of 75,700 shares [2] - Boteng Co.: closed at 23.34, down 6.27% with a trading volume of 224,900 shares [2] - Kailaiying: closed at 105.42, down 5.04% with a trading volume of 57,800 shares [2] Capital Flow - The medical services sector saw a net outflow of 870 million yuan from institutional investors, while retail investors contributed a net inflow of 601 million yuan [2][3] - Key stocks with significant capital flow included: - Sanbo Brain Science: net inflow of 21.51 million yuan from institutional investors [3] - International Medical: net inflow of 20.51 million yuan from institutional investors [3] - Jiuzhou Pharmaceutical: net inflow of 10.59 million yuan from institutional investors [3]

Group 1 - Pharmaceutical stocks continue to decline, with CRO sector leading the drop, including significant declines in Junshi Biosciences (down 7.98%), Kanglong Chemical (down 6.3%), Kelaiying (down 5.69%), and Tigermed (down 3.48%) [1] - Recent market trends in the pharmaceutical sector are attributed to several factors, including a deal between the Trump administration and Pfizer to lower drug prices in the U.S., which is seen as a reconciliation signal between U.S. pharmaceutical companies and the government [1] - The U.S. Senate's consideration of a bill to prohibit certain Chinese biotech companies from receiving federal funding has led to a significant pullback in the CXO sector [1] Group 2 - Recent tensions in U.S.-China trade relations have escalated, with a renewed tariff war expected; however, the pharmaceutical market is not overly concerned as the industry has shown resilience since the first tariff war in April [2] - The innovative drug and CXO sectors have outperformed other sub-industries, driven by China's rising independent innovation and ongoing overseas business development, which are less affected by tariffs [2] - The CXO sector benefits from strong upstream and downstream relationships and a service pricing model that allows companies to pass on tariff pressures relatively freely [2]

Core Viewpoint - 凯莱英's stock price has shown significant growth this year, with a year-to-date increase of 48.57%, indicating strong market performance and investor interest [1][2]. Financial Performance - For the first half of 2025, 凯莱英 reported revenue of 3.188 billion yuan, representing a year-on-year growth of 18.20%, and a net profit attributable to shareholders of 617 million yuan, up 23.71% [2]. - CMO services account for 76.19% of 凯莱英's main business revenue, while emerging services contribute 23.71% [1]. Stock Market Activity - As of October 9, 凯莱英's stock price was 111.42 yuan per share, with a market capitalization of 40.177 billion yuan [1]. - The stock has experienced a net outflow of 21.6685 million yuan in principal funds, with significant trading activity reflected in the buying and selling volumes [1]. Shareholder Information - As of June 30, 2025, 凯莱英 had 41,300 shareholders, a decrease of 5.16% from the previous period [2]. - The top ten circulating shareholders include notable funds, with 中欧医疗健康混合A holding 16.2843 million shares, a decrease of 27,500 shares from the previous period [3].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 凱萊英醫藥集團（天津）股份有限公司 呈交日期: 2025年10月8日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06821 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 27,553,260 | RMB | | | 1 RMB | | 27,553,260 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 27,553,260 | RMB | | | 1 RMB | | 27,553,260 | | 2. 股份分類 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 本月底法定/註冊股本總額： RMB 360,593,720 致：香港交易及結算所有限公司 公司名稱: 凱萊英醫藥集團（天津）股份有限公司 呈交日期: 2025年10月8日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06821 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 27,553,260 | RMB | | | 1 RMB | | 27,553,260 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 27,553,260 | RMB | | | 1 RMB | | 27,553,260 | | 2. ...

Core Viewpoint - Kailaiying's stock price has shown significant growth this year, with a year-to-date increase of 49.53%, indicating strong market performance and investor interest [1][2]. Financial Performance - For the first half of 2025, Kailaiying achieved a revenue of 3.188 billion yuan, representing a year-on-year growth of 18.20%, and a net profit attributable to shareholders of 617 million yuan, up 23.71% [2]. - The company has distributed a total of 2.405 billion yuan in dividends since its A-share listing, with 1.701 billion yuan distributed over the past three years [3]. Stock Market Activity - As of September 30, Kailaiying's stock was trading at 112.14 yuan per share, with a market capitalization of 40.437 billion yuan and a trading volume of 585 million yuan [1]. - The stock has seen a net inflow of 8.6225 million yuan from major funds, with significant buying and selling activity from large orders [1]. Shareholder Structure - As of June 30, 2025, Kailaiying had 41,300 shareholders, a decrease of 5.16% from the previous period, with an average of 0 shares per shareholder [2]. - The top shareholders include various funds, with notable changes in holdings among major institutional investors [3].